Company intelligence / Profile preview
Spriaso
Salt Lake City, Utah, United Statesspriasollc.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Commercial
01
Overview
Spriaso has developed and received FDA approval for Tuxarin ER®, a long acting codeine/chlorpheniramine combination antitussive product. The company’s portfolio includes several proprietary CNS and GI disorder candidates that have completed proof-of-principle clinical studies and are expected to proceed to NDA filing. Products are available for out-license and protected by multiple patents. No active clinical trials are currently listed on ClinicalTrials.gov.
- Therapeutic areas
- GastroenterologyPulmonologyNeurology
- Modalities
- Small moleculeCombination product (codeine + chlorpheniramine)Drug delivery platform
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Nexgen Pharma (co-development/manufacturing partner for Tuxarin ER®/Rinotuss12®)
Beyond the preview
Go deeper on Spriaso.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spriaso.